Abstract
DLK1 is a newly identified prognostic factor associated with liver cancer survival. To prepare specific monoclonal antibody (MAb) against DLK1, cDNA of DLK1 was cloned by RT-PCR and inserted into prokaryotic expression vector pGEX-4T1, respectively. The fusion proteins were expressed in Escherichia coli. Monoclonal antibody against DLK1 was obtained with hybridoma technique and specific ELISA screening. Western blotting and immunohistochemistry assays showed that MAb 6D6 had specific binding ability with DLK1 protein in eukaryotic cells and cancer tissues. This MAb will be a helpful tool for the detection of DLK1 protein in the tissues and serum of liver cancer and other cancer patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
